LENZ Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.74) Per Share, William Blair Forecasts (NASDAQ:LENZ)

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Research analysts at William Blair issued their Q1 2024 earnings per share estimates for shares of LENZ Therapeutics in a report released on Monday, April 15th. William Blair analyst T. Lugo expects that the company will earn ($0.74) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for LENZ Therapeutics’ Q2 2024 earnings at ($0.46) EPS, Q3 2024 earnings at ($0.46) EPS, Q4 2024 earnings at ($0.44) EPS, FY2024 earnings at ($2.10) EPS and FY2025 earnings at ($2.95) EPS.

Several other equities research analysts have also commented on the company. SVB Leerink began coverage on LENZ Therapeutics in a research report on Monday. They set an “outperform” rating and a $32.00 target price on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of LENZ Therapeutics in a research note on Monday. Citigroup began coverage on LENZ Therapeutics in a research note on Wednesday, April 10th. They set a “buy” rating and a $34.00 price target on the stock. Finally, Piper Sandler began coverage on LENZ Therapeutics in a research note on Wednesday, March 27th. They set an “overweight” rating and a $28.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, LENZ Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $31.33.

LENZ Therapeutics Stock Performance

Shares of LENZ Therapeutics stock opened at $17.70 on Wednesday. LENZ Therapeutics has a one year low of $14.07 and a one year high of $29.82. The stock has a market cap of $147.26 million, a P/E ratio of -1.13 and a beta of 0.20.

Insider Transactions at LENZ Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 998,009 shares of the stock in a transaction dated Thursday, March 21st. The stock was purchased at an average cost of $15.03 per share, with a total value of $15,000,075.27. Following the completion of the purchase, the director now directly owns 3,319,339 shares in the company, valued at approximately $49,889,665.17. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 38.40% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.